Sucrosofate (potassium)

• UNSPSC Description:

  Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398[1][2].

• Target Antigen:

  Biochemical Assay Reagents

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/sucrosofate-potassium.html

• Solubility:

  H2O : 175 mg/mL (ultrasonic)

• Smiles:

  O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)(O[K])=O

• Molecular Weight:

  1287.52

• References & Citations:

  [1]Ko A H, Tempero M A, Shan Y S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer[J]. British journal of cancer, 2013, 109(4): 920-925.|[2]Klinz S G, Zheng J, De Souza R, et al. Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F] FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): C293-C293.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  73264-44-5